The outlook of companies tied to the drug's legacy presents a challenging investment scenario . While the initial success generated substantial profits , generic competition have significantly impacted revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of proprietary rights , evolving healthcare trends , an